CYDY and Struggle for Power (through the eyes of a little

New Post Public Reply Private Reply Replies (1) Message Board
Cycl2R
754
CYDY and Struggle for Power (through the eyes of a little guy).

Let's start with establishing two certainties before building a set of speculations upon them.

Axiom #1. Everything that happens in this country between now and November is subordinate to the struggle for power at least for the next four years and more likely for much longer because the establishment must have learned the lessons of its 2016 defeat and will “save” the people of the United States (aka the ‘deplorables’) from repeating it.

Axiom #2. The old adage that "When it comes to health care, nothing is nonpartisan” sounds as gross understatement in our present situation and thus it is axiomatic that with the increasing volume of news about the miraculous healing powers of Leronlimab, our miracle molecule has finally appeared and is rising ever bigger in the periscopes--or should we say 'microscopes'--of both party machines, their strategists, their PACs, their foundations, their corporate allies and their moles in state agencies.

The rest is pure speculation.

First, let's look at Leronlimab through the lenses of the Dem's allied forces lining up on the battlefield for the November Armageddon. They must really hate what they see. This drug is a “game changer” not only for economy, but for politics as well. If Leronlimab gets the emergency authorization, it will be allowed to protect the American people from Covid-19 and fear, and return the nation to work . Trump will be saved, announce himself to be something colorful like the Father of the Nation, and will most likely win the second term. This cannot be allowed to happen. Period! Too much is at stake for people who really count. But not allowed only before November. Afterwards it will depend on the elections results and a myriad of related factors. Timing is very important here because the FDA will have to decide on our BLA by then. Earlier, a number of CYDY investors here, including myself, expressed the opinion that the FDA is in bed with Gilead who stands to suffer colossal losses in case we are approved for as little as the HIV Combo. According to my observations, this “conspiracy theory” has been getting more traction here recently (Welcome to the Club!). The danger to Gilead was serious enough even before Covid-19 situation, it is tenfold now, when we have learned about Lero’s preventive powers against coronavirus and metastatic cancer. What would the average HIV patient decide facing a choice between the Gilead’s daily basket of pills and once-a-week shot of Vyrologix which saves him from HIV devastations and, TO BOOT, empowers his immune system to protect him from all the ravages of Covid-19 and twenty plus lethal cancers FREE OF CHARGE?! What will you choose in his place?

These are main reasons FOR NOW why I think that between now and November the Dems Armada and Gilead will remain natural allies against our little molecule and little us. Or to put it differently, there is no hope that the money behind Biden and all his men will go to support CYDY, and this includes the high-tech money of Bill Gates Foundation and the rest of them. But money is not everything. What about the FDA (apart from its relation with Gilead) and national media networks?

Hahn was appointed by Trump but I am afraid this doesn’t mean a thing. For just as it was the case with appointing Fauci and stuffing the Panel on COVID-19 Treatment with Gilead people, Trump could only follow the will of his advisors like the Gilead mole Joe Grogan. By its very nature as a state agency in the business of regulating a high-tech industry which overwhelmingly supported Clinton in 2016, the FDA is much more likely to sympathize with anti-Trump forces. Very soon, especially following the publication of Dr. Patterson's article, the agency will come under under tremendous backroom pressure from the Dems to keep CYDY under the radar as much as possible and by no means approve any indication of it before November.

What about the press? In this country, “free press” of any national significance is in the hands of anti-Trump forces. Fox being only exception. But Fox is not so much pro-Trump as pro-Big Business. And this means BP. So if Fox is to decide between Trump and BP, its choice is obvious.

If these reflections are not completely off the mark, what are then our chances for approval as seen in the cross-hairs of the struggle for power between now and November? Our chances are slim. Trump is the only one who must be absolutely interested in a drug which will all but guarantee his second term. Only Leronlimab can do this. However the POTUS is encircled by a moat of his medical ‘advisors’ some of who are doubtfully loyal to him and others vetted by BP. Armed only with pitchforks and table knives we, little guys, must find the way to get through the advisor’s moat and the castle walls of the “free press” to deliver Trump the good news of Leronlimab.
6

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Fogg Law Triumphs with $2M Verdict in Stillbirth Case

Updated Category News Views 7

The Gavel Falls: A Bittersweet Victory Some days there's a silver lining in a court's decision that brings cold comfort. Fogg Law Group recently notched a $2 million verdict for a heartbroken family in Florida who took on a medical malpractice fight for justice. This dusty legal arena in Lee County just saw a verdict that couldn't make past losses disappear, yet shone a...

Continue Reading
Revolutionizing Taco Orders: AI Takes the Lead at Torchy’s

Updated Category News Views 95

Transforming the Taco Ordering Experience Torchy’s Tacos, known for their flavorful offerings and unique menu, has taken a significant leap forward in enhancing customer service with the integration of SoundHound’s advanced voice AI technology. This innovation is now live across all 130 locations, enabling guests to place orders using natural speech just as if they...

Continue Reading
Wolters Kluwer's Recent Share Buyback Insights and Impact

Updated Category News Views 133

Wolters Kluwer's Share Buyback Program Explained Wolters Kluwer, a prominent player in professional information and software solutions, is taking significant steps to enhance shareholder value through its share buyback program. Recently, the company announced it has repurchased a substantial number of its own shares, aiming to invest in its future while providing returns...

Continue Reading
Wolters Kluwer's Latest Share Buyback Update and Insights

Updated Category News Views 344

Wolters Kluwer's Commitment to Shareholders In recent financial activities, Wolters Kluwer, a renowned global leader in professional information and software solutions, has engaged in significant share repurchase transactions. This effort not only reflects the company’s strong financial standing but also underscores its commitment to returning value to shareholders....

Continue Reading
Lifecore Biomedical Prepares for Exciting Virtual Investor Day

Updated Category News Views 43

Lifecore Biomedical Prepares for Exciting Virtual Investor Day Lifecore Biomedical, Inc. (NASDAQ: LFCR), a distinguished contract development and manufacturing organization (CDMO), is set to host an engaging virtual investor day. Scheduled for a time just prior to market open, this event promises to be a pivotal opportunity for shareholders and potential investors alike....

Continue Reading